Page 23 - Haematologica Vol. 110 - January 2025

EDITORIAL
M. Quijada-Álamo et al.
References
1. Minhajuddin M, Winters A, Ye H, et al. Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia. Haematologica. 2025;110(1):103-116.
2. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984.
3. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107(11):4532-4539.
4. Carter BZ, Mak PY, Mu H, et al. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016;8(355):355ra117.
5. Roberts AW, Wei AH, Huang DCS. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood. 2021;138(13):1120-1136.
6. Goff DJ, Recart AC, Sadarangani A, et al. A pan-BCL2 inhibitor
renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 2013;12(3):316-328.
7. Adnan-Awad S, Kankainen M, Mustjoki S. Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia. Leuk Lymphoma. 2021;62(9):2064-2078.
8. Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315-2326.
9. Moujalled DM, Hanna DT, Hediyeh-Zadeh S, et al. Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. Blood Adv. 2020;4(12):2762-2767.
10. Parry N, Busch C, Aßmann V, et al. BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia. Cell Death Discov. 2022;8(1):457.
Haematologica | 110 January 2025
15